Hiang-Keat Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2529017/publications.pdf

Version: 2024-02-01

18	295	7	14
papers	citations	h-index	g-index
18	18	18	653
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Perception of disease, well-being and financial burden by patients with chronic hepatitis B: A self-reported assessment. Annals of the Academy of Medicine, Singapore, 2022, 51, 378-380.	0.4	O
2	Virtual monitoring for stable chronic hepatitis B patients does not reduce adherence to medications: A randomised controlled study. Journal of Telemedicine and Telecare, 2021, , 1357633X2098029.	2.7	1
3	Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites. American Journal of Gastroenterology, 2021, 116, 1437-1446.	0.4	5
4	New-onset cardiovascular risk factors following liver transplantation: A cohort analysis in Singapore. Annals of the Academy of Medicine, Singapore, 2021, 50, 548-555.	0.4	1
5	Hepatic venous-portal gradient (HVPG) measurement: pearls and pitfalls. British Journal of Radiology, 2021, 94, 20210061.	2.2	7
6	Clinical validation of the chronic liver disease questionnaire for the Chinese population in Singapore. JGH Open, 2020, 4, 191-197.	1.6	2
7	PS-141-CyTOF-based immune monitoring of HBV-HCC patients receiving autologous anti-tumour T-cell therapy. Journal of Hepatology, 2019, 70, e89-e90.	3.7	0
8	A randomised clinical trial of the safety, cost effectiveness and patient experience of nurseâ€led telemonitoring of chronic hepatitis B patients. GastroHep, 2019, 1, 249-255.	0.6	2
9	Translation and cultural adaption of the Chronic Liver Disease Questionnaire for the Mandarin-speaking Chinese population in Singapore through cognitive debriefing. Proceedings of Singapore Healthcare, 2019, 28, 48-54.	0.6	1
10	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	1.3	92
11	Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis. Gastroenterology, 2019, 157, e26-e27.	1.3	8
12	Sa1640 The Use of Albumin in Decompensated Cirrhosis: Are the Indications Approrpriate and the Desired Outcomes Achieved?. Gastroenterology, 2016, 150, S1083-S1084.	1.3	0
13	Sa1631 Weight Change, Non-Alcoholic Fatty Liver Disease and Metabolic Complications Post-Liver Transplantation. Gastroenterology, 2016, 150, S1081.	1.3	0
14	Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Digestive Diseases and Sciences, 2016, 61, 3084-3092.	2.3	23
15	Clinical applications, limitations and future role of transient elastography in the management of liver disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 91.	1.1	54
16	Longâ€term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 389-395.	2.8	66
17	Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. Gastroenterology Report, 2015, 3, 122-127.	1.3	26
18	Acute Abdomen Secondary to Incarcerated Umbilical Hernia after Treatment of Massive Cirrhotic Ascites. Case Reports in Hepatology, 2013, 2013, 1-3.	0.7	7